Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
Jean‐Louis Vincent(Université Libre de Bruxelles), Donat R. Spahn, Yves Ozier(Centre Hospitalier Régional Universitaire de Brest), Rolf Rossaint(Unknown), David Zideman(Imperial College Healthcare NHS Trust), Bruno Riou(Unknown)
Cited by 384
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k